

I hereby certify that, on the date shown below, this correspondence is being:  
☐ deposited with the United States Postal Service in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,  
☒ under 37CFR § 1.8(a), with sufficient postage as first class mail, or  
☐ under 37CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label No.

**PATENT**

☐ transmitted by facsimile to the Patent and Trademark Office, Fax Number \_\_\_\_\_.

Atty. Docket No.  
AR0 3080 USA R1

Date: 02/27, 2004 By: Jolanta Pence  
Jolanta Pence

CN 27777


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Gilbert et al.

Serial No.: 10/603,513

Filed: June 24, 2003

For: REUSABLE, SPRING DRIVEN  
AUTOINJECTOR



Group Art Unit: 3763

Examiner: Unassigned

**INFORMATION DISCLOSURE  
STATEMENT**

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the



☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2). (The U.S. patents and each U.S. patent application publication listed on the attached Form PTO-1449 are not enclosed because this U.S. patent application was filed after June 30, 2003 or this international application has entered the national stage under 35 USC §371 after June 30, 2003 (see USPTO waiver of requirement under 37 CFR 1.98 (a)(2)(i)).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750.

Date: 2/26/04

ALZA CORPORATION  
c/o Johnson & Johnson  
One Johnson & Johnson Plaza, WH3221  
New Brunswick, NJ 08933  
Customer No.: 27777

Respectfully submitted,

  
Attorney for Applicants

Samuel E. Webb, Reg. No.: 44,394  
Tel. No.: 650-564-5106  
Fax. No. 650-564-2195

mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or

☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or


☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/603,513
Filing Date	June 24, 2003
First Named Inventor	Scott Gilbert
Group Art Unit	3763
Examiner Name	
Attorney Docket Number	ARC 3080 R1

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy\	Pages, Columns, Lines, here relevant passages or relevant figures
		Number	Kind Code <sup>2</sup> (if known)			
		3,797,489		Sarnoff	03-19-1974	
		4,518,384	A	Tarello	05-21-1985	
		4,678,461		Mesa	06-07-1987	
		4,894,054		Miskinyar	01-16-1990	
		5,092,843	A	Manroe et al.	03-03-1992	
		5,102,393	A	Sarnoff et al.	04-07-1992	
		5,155,965	A	Tabei et al.	10-20-1992	
		5,300,030	A	Crossman et al.	04-05-1994	
		5,354,286	A	Mesa et al.	10-11-1994	
		5,527,287	A	Miskinyar	06-18-1996	
		5,567,160	A	Massino	10-22-1996	
		5,665,071	A	Wyrick	09-09-1997	
		5,695,472	A	Wyrick	12-09-1997	
		5,957,897	A	Jeffrey	09-28-1999	
		6,099,504	A	Gross et al.	6,099, 504	
		6,149,626	A	Bachynsky	11-21-2000	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T 6
		Number <sup>4</sup>	Office	Code <sup>5</sup>				
	X	0982518	EP	A2	Eagle Ind. Co. Ltd.	03-01-2000		
	+	94/13342	WO		Greco	06-23-1994		
	+	95/29720	WO		PA Consulting Services LTD	11-09-1995		
	+	95/31235	WO		Washington Biotech Corp.	11-23-1995		
	X	98/00188	WO		Pharmacia & Upjohn AB	01-08-1998		
	+	01/17593	WO		Computer Controlled Syringe INC.	03-15-2001		
Examiner signature						Date Considered		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



(use as many sheets as necessary)

<b>Application Number</b>	10/603,513
<b>Filing Date</b>	June 24, 2003
<b>First Named Inventor</b>	Scott Gilbert
<b>Group Art Unit</b>	3763
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	ARC3080 R1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.